IMM-529 IND: currently under review, FDA request for Information – minor updates to clinical protocol completed and submitted Travelan® P2TD (n=851) Uniformed Services University study topline data delayed to the end of November due to U.S government shutdown MELBOURNE, Australia, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company provides a clinical trial update on Travelan® and IMM-529. IMM-529 IND (Clostridioid ...

Core Insights - Immuron Limited (NASDAQ:IMRN) reported a 49% growth in global revenue for fiscal year 2025, primarily driven by strong sales of its flagship product, Travelan [1][2] - The company achieved a net loss reduction of 24% year-over-year, with a loss per share of A$0.023 for FY2025, an improvement from A$0.03 in FY2024 [2] - Gross margins remained robust at 65.4%, indicating strong profitability despite the losses [2] Revenue Performance - North American sales for Travelan increased by 76% to A$2 million, attributed to growth in Amazon and Canadian retail [1] - Australian sales rose 40% to A$5.3 million, supported by the introduction of new pharmacy channels [1] Financial Position - At year-end, Immuron held AU$2.83 million in cash, a decrease from AU$11.66 million the previous year [2] - Shareholders' equity decreased to AU$8 million from AU$12.7 million in 2024, reflecting a decline in overall financial strength [2] - The company maintained minimal long-term debt, indicating a stable balance sheet [2]

Sales Performance - Immuron Limited reported annual sales of AUD$7.3 million, representing a 49% increase compared to the previous year [1][3] - For the June 2025 quarter, sales reached AUD$2.0 million, up 55% year-over-year [1] - In Australia, annual sales were AUD$5.2 million, a 40% increase from the prior year, with June 2025 quarter sales of AUD$1.5 million, up 58% [1][3] - North American sales totaled AUD$2.0 million, reflecting a 76% increase year-over-year, with June 2025 quarter sales of AUD$0.5 million, up 49% [1][3] Product Overview - Travelan is an over-the-counter immune supplement designed to target pathogenic bacteria and their toxins in the gastrointestinal tract [1][4] - It is an orally administered passive immunotherapy that helps reduce the likelihood of travelers' diarrhea, caused primarily by enterotoxigenic Escherichia coli (ETEC) [4][5] - Travelan is recognized as a listed medicine in Australia and a licensed natural health product in Canada, while in the U.S., it is marketed as a dietary supplement [4] Strategic Focus - The company aims to position Travelan as an essential product for travelers, with a clear growth strategy supporting its sales increase [3] - Immuron plans to invest further in North America while maintaining momentum in the Australian market [3]